On March 12, 2010, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) released recommendations for the 13-valent pneumococcal conjugate vaccine (PCV13). Currently Wyeth is only marketing Prevnar 13 (www.cdc.gov/vaccines/pubs/vis/default.htm#pcv), which replaces Prevnar (PCV7). The Current Procedural Terminology (CPT®) code for Prevnar 13 is 90670, and the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code is V03.82. Report these codes in addition to the appropriate immunization administration code (90465–90474).

ACIP recommends PCV13 for all children aged 2 through 59 months. ACIP also recommends PCV13 for children aged 60 through 71 months with an underlying medical condition that increases the risk for pneumococcal disease or complications. Those underlying medical conditions are listed in the ACIP additional recommendations for PCV13 immunization.

Healthy children aged 24 through 59 months who have never received a PCV7 or PCV13 vaccine, or...

You do not currently have access to this content.